Prevalence and outcomes of atrial fibrillation in a European healthcare area gained through the processing of a health information technology system

Rodríguez‐Mañero, Moisés; López-Pardo, Estrella; Cordero, Alberto; Martínez‐Sande, José Luis; Peña-Gil, Carlos; Platas, José Novo; García‐Seara, Javier; Mazón, Pilar; Román, Alfonso Varela; Garcı́a-Acuña, José Marı́a; González-Juanatey, José Ramón

doi:10.1016/j.repc.2018.06.008

Cited by 7 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 More recent population-based studies have reported similar prevalence estimates in European countries. [7][8][9] Even within the relatively homogenous Nordic countries, the prevalence estimates vary. In Denmark, the cumulative prevalence of AF was reported to be 2.0% among the whole population from 1983 to 2012.…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Incidence Rates of Atrial Fibrillation in Denmark 2004–2018

Hegelund¹,

Kjerpeseth²,

Mortensen³

et al. 2022

CLEP

View full text Add to dashboard Cite

To estimate the prevalence and incidence of atrial fibrillation (AF) in Denmark during 2004-2018 and to investigate whether methodological choices influence these estimates. Patients and Methods: A register-based cohort study was conducted of all individuals aged ≥18 years in Denmark 2004-2018. The cumulative prevalence of AF at the end of the study period was calculated as the number of AF cases alive with at least one inpatient or two outpatient diagnoses during 1994-2018 divided by the number of Danish residents in 2018. Incidence rates were calculated as the number of annual AF cases with no previous diagnosis in the past 10 years (ie, a 10-year washout period) divided by the person-time contributed by the population free of AF on 1 January in the same calendar year. Furthermore, the influence of varying case definitions was investigated. Results: The cumulative prevalence of AF was 3.0% in 2018. The incidence rate increased from 391 to 481 per 100,000 person-years (PYs) from 2004 to 2015 (1.7% average annual increase) after which it declined to 367 per 100,000 PYs in 2018 (8.5% average annual decrease). This pattern was observed in both sexes irrespective of age. Methodological choices, particularly the case definition's strictness and the length of the washout period, had a substantial influence on the reported estimates. Conclusion:The cumulative prevalence of AF is currently around 3.0% in the Danish population, but the incidence has declined since 2015. As these estimates are influenced by methodological choices, future studies should strive for precise reporting of study methodology.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence and Incidence Rates of Atrial Fibrillation in Denmark 2004–2018

Hegelund¹,

Kjerpeseth²,

Mortensen³

et al. 2022

CLEP

View full text Add to dashboard Cite

show abstract

“…Atrial fibrillation (AF), the most common arrhythmia, is associated with increased risk for cardiac thromboembolism 1 . AF is present in approximately 1% to 2% of the population 2 and associated with increased risk for cardiac thromboembolism, 1 causing almost a third of all strokes 3 . Thromboembolism and stroke risk can be greatly reduced if oral anticoagulants (OACs, including both vitamin K antagonists [VKAs] and direct oral anticoagulants [DOACs]) are administered, but this treatment increases bleeding risk 4,5 .…”

Section: Introductionmentioning

confidence: 99%

Novel bleeding risk score for patients with atrial fibrillation on oral anticoagulants, including direct oral anticoagulants

Adam

Feller

Syrogiannouli

et al. 2021

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…Atrial brillation (AF) is the most common sustained cardiac arrhythmia in the world and is associated with signi cant symptoms, impaired quality of life, and cardiovascular morbidity and mortality. [1][2][3] Stroke prevention is among the primary therapeutic goals in managing AF. Clinical guidelines for AF recommend using long-term oral anticoagulant therapy driven by individually predicted stroke risk.…”

Section: Introductionmentioning

confidence: 99%

In vitro evaluation of anticoagulant therapy management when urgent percutaneous coronary intervention is required in rivaroxaban-treated patients

Melek

Arı

et al. 2023

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Objectives: We investigated in vitro the management of intraprocedural anticoagulation in patients requiring immediate percutaneous coronary intervention (PCI) while using regular direct oral anticoagulants (DOACs).Materials and methods: Twenty-ve patients taking 20mg of rivaroxaban once daily comprised the study group, while ve healthy volunteers included the control group. In the study group, a beginning (24 hours after the last rivaroxaban dose) examination was performed. Then, the effects of basal and four different anticoagulant doses (50 IU/kg unfractionated heparin (UFH), 100 IU/kg UFH, 0.5 mg/kg enoxaparin, and 1 mg/kg enoxaparin) on coagulation parameters were investigated at the 4th and 12th hours following rivaroxaban intake. The effects of four different anticoagulant doses were evaluated in the control group. The anticoagulant activity was assessed mainly by anti-factor Xa (anti-Xa) levels.Results: Beginning anti-Xa levels were signi cantly higher in the study group than in the control group (0.69±0.77 IU/mL vs. 0.20±0.14 IU/mL; p <0.05). The study group's 4th and 12th-hour anti-Xa levels were signi cantly higher than the beginning level (1.96±1.35 IU/mL vs. 0.69±0.77 IU/mL; p <0.001 and 0.94±1.21 IU/mL vs. 0.69±0.77 IU/mL; p <0.05, respectively). Anti-Xa levels increased signi cantly in the study group with the addition of UFH and enoxaparin doses at the 4th and 12th hour than the beginning (p <0.001 at all doses). The safest anti-Xa level (from 0.94±1.21 IU/mL to 2.00±1.02 IU/mL) was achieved 12 hours after rivaroxaban with 0.5mg/kg enoxaparin. Conclusion: Anticoagulant activity was su cient for urgent PCI at the 4th hour after rivaroxaban treatment, and additional anticoagulant administration may not be required at this time. Twelve hours after taking rivaroxaban, administering 0.5mg/kg of enoxaparin may provide adequate and safe anticoagulant activity for immediate PCI. This experimental study result should con rm with clinical trials (NCT05541757).

show abstract

Prevalence and outcomes of atrial fibrillation in a European healthcare area gained through the processing of a health information technology system

Cited by 7 publications

References 15 publications

Prevalence and Incidence Rates of Atrial Fibrillation in Denmark 2004–2018

Prevalence and Incidence Rates of Atrial Fibrillation in Denmark 2004–2018

Novel bleeding risk score for patients with atrial fibrillation on oral anticoagulants, including direct oral anticoagulants

In vitro evaluation of anticoagulant therapy management when urgent percutaneous coronary intervention is required in rivaroxaban-treated patients

Contact Info

Product

Resources

About